• Record $89.0m in net sales contracts for FY26
• $48.3m of contracted future revenue expected in FY27
• Contracted Clinical Trials revenue up 58% for FY27

Cogstate Ltd (ASX:CGS) announced a business update for the quarter ended 30 June 2026 (4Q26) and for the full year to 30 June 2026 (FY26). Net sales contracts executed during 4Q26 totalled $21.9 million, bringing the total value over the year to 30 June 2026 to a record total of $89.0 million, an increase of 116% from the $41.3 million executed in FY25. Following a record year for sales contracts in FY26, Cogstate enters FY27 with contracted future revenue of $118.5 million, representing a 32% increase on the prior year. Of this, $48.3 million is expected to be recognised as revenue in FY27, up 54% from the same time last year. Contracted Clinical Trials revenue for FY27 is $46.1 million, up 58% from $29.2 million at 30 June 2025. Contracted Healthcare revenue for FY27 is flat, year to year, at $2.3 million.

FY27 contracted future revenue of $118.5 million

Cogstate expects continued growth in contracted future revenue for FY27, driven by increased demand in Clinical Trials.